Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Puma Biotechnology Inc Market Cap
From what 3 stock analysts predict, the share price for Puma Biotechnology Inc (PBYI) might increase by 27.83% in the next year. This is based on a 12-month average estimation for PBYI. Price targets go from $2 to $7. The majority of stock analysts believe PBYI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 3 Wall Street analysts have assigned PBYI 1 buy ratings, 1 hold ratings, and 1 sell ratings. This means that analysts expect Puma Biotechnology Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PBYI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of PBYI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Nov 20, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Nov 8, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 2, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Jul 26, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Jun 4, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | Jun 3, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | May 20, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Reiterates | May 3, 2024 |
| Edward White HC Wainwright & Co. | Buy | $7 | Maintains | Mar 1, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Feb 13, 2024 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Sep 20, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Aug 4, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Jun 5, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | May 5, 2023 |
| Edward White HC Wainwright & Co. | Buy | $8 | Reiterates | Mar 6, 2023 |
HC Wainwright & Co. | Buy | Maintains | Aug 31, 2022 | |
| Edward White HC Wainwright & Co. | Buy | $8 | Maintains | Aug 5, 2022 |
HC Wainwright & Co. | Buy | $12 | Maintains | May 6, 2022 |
Citigroup | Buy | Upgrade | Sep 28, 2021 | |
| Kennen MacKay RBC Capital | Sector Perform | $6 | Maintains | Aug 6, 2021 |
When did it IPO
2012
Staff Count
185
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Alan H. Auerbach
Market Cap
$154.1M
In 2023, PBYI generated $235.6M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PBYI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Puma Biotechnology has commenced the phase II ALISCA-Breast1 study of alisertib for hormone receptor-positive, HER2-negative metastatic breast cancer treatment.
Why It Matters - Puma's phase II study on alisertib may indicate potential breakthroughs in breast cancer treatment, impacting stock performance and future revenue prospects for the company.
Wed, 20 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Puma Biotechnology has begun a clinical trial for alisertib combined with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.
Why It Matters - Puma Biotechnology's trial of alisertib signals potential advancements in breast cancer treatment, which could enhance its market position and attract investor interest in future growth.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Puma Biotechnology exceeded Q3 2024 earnings and revenue estimates and has updated its financial guidance for the year.
Why It Matters - Puma Biotechnology's stronger-than-expected earnings and updated guidance signal growth potential, which can boost investor confidence and influence stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Puma Biotechnology, Inc. (NASDAQ:PBYI) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring key company executives.
Why It Matters - The Q3 earnings call will provide insights into Puma Biotechnology's financial performance and strategic direction, influencing stock valuation and investor sentiment.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Puma Biotechnology reported its 3Q-2024 earnings results on Nov. 7 and held a conference call to discuss the details.
Why It Matters - Puma Biotechnology's 3Q-2024 earnings results and conference call may signal financial performance trends, impacting stock valuation and investor sentiment.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Puma Biotech (PBYI) reported Q3 earnings of $0.45 per share, surpassing the Zacks estimate of $0.35 and increasing from $0.17 per share year-over-year.
Why It Matters - Puma Biotech's earnings beat estimates and showed significant year-over-year growth, indicating strong performance and potential for future profitability, positively influencing investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
